NEW YORK (GenomeWeb) – MDxHealth today announced a partnership with SouthGenetics to market its ConfirmMDx test for prostate cancer in Latin America.
Under the terms of the agreement, Montevideo, Uruguay-based SouthGenetics secures rights to commercialize ConfirmMDx for Prostate Cancer in Argentina, Bolivia, Chile, Colombia, the Dominican Republic, Ecuador, Mexico, Peru, Panama, Paraguay, Uruguay, and Venezuela. Financial and other details of the agreement were not disclosed.
All tests will be processed at MDxHealth's CLIA-certified laboratory in Irvine, California.
The firm said in a statement that more than 160,000 cases of prostate cancer are diagnosed every year in Latin America. The ConfirmMDx test looks at epigenetics associated with prostate cancer to identify men who do not need repeat biopsies.
The deal comes as MDxHealth continues to expand availability of the prostate cancer test. In September, the Belgian firm signed a deal to make ConfirmMDx available to members in the Tufts Health Plan.